NASDAQ:ADXS
Advaxis Stock News
$0.540
+0 (+0%)
At Close: Apr 24, 2024
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
06:00am, Tuesday, 06'th Jul 2021
– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelod
Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
04:05pm, Monday, 14'th Jun 2021
ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA®
Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List
02:38pm, Thursday, 27'th May 2021
Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and
3 Penny Stocks To Watch Under $2 Making Big Moves Today
12:06pm, Thursday, 20'th May 2021
Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, P
Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda
10:17am, Thursday, 20'th May 2021
Advaxis Inc (NASDAQ: ADXS) announced updated data from its Phase 1/2 study evaluating ADXS-503 in combination with Merck & Co Inc's Keytruda (pembrolizumab) in patients with metastatic non-small-ce
Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab
Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25%
12:25pm, Wednesday, 19'th May 2021
Best biotech penny stocks to buy during the crypto crash? Check these 3 out The post Biotech Penny Stocks Pushing Up During The Crypto Crash, One Up 25% appeared first on Penny Stocks to Buy, Picks, N
Advaxis (ADXS) Stock: Over 25% Increase Pre-Market Explanation
07:52am, Wednesday, 19'th May 2021
The stock price of Advaxis, Inc. (NASDAQ: ADXS) increased by over 25% pre-market. This is why it happened.
Advaxis: New Early Stage Pipeline Offers Significant, But Risky Upside
10:15pm, Saturday, 15'th May 2021
Advaxis, Inc. is a small clinical-stage biotechnology company developing oncological therapeutics with their live attenuated Listeria monocytogenes antigen-delivery platform technology. Advaxis is cur
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
04:30pm, Wednesday, 28'th Apr 2021
PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, tod
UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies
11:07am, Monday, 26'th Apr 2021
Non-dilutive capital will support advancement of ADXS-HOT neoantigen program Non-dilutive capital will support advancement of ADXS-HOT neoantigen program
ADVAXIS MAKING BOLD STEPS IN NEW CANCER STUDIES AND AGREEMENT WITH COLUMBIA UNIVERSITY
01:06pm, Tuesday, 20'th Apr 2021
Advaxis, Inc. (NASDAQ: ADXS), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:30am, Monday, 12'th Apr 2021
PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunot
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade
Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting
08:00am, Friday, 12'th Mar 2021
PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and
